AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
26-06-26	€0.8740	+1.86%	259,326
26-06-25	€0.8580	-1.38%	58,599
26-06-24	€0.8700	+0.23%	77,828
26-06-23	€0.8680	-0.23%	179,601
26-06-22	€0.8700	-2.79%	155,689

Real-time Euronext Paris

More quotes

Income Statement and Estimates

More financial data

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-06-26 am EDT			5-day change	1st Jan Change
0.8740 ^EUR	+1.86%		-2.35%	-43.10%

Jun. 18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
Jun. 18	AB Science Secures New U.S. Patent for Masitinib

Market Cap	66.9M 76.15M 61.69M 57.72M 108M 7.18B 110M 741M 287M 3.55B 286M 280M 12.32B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	66.9M 76.15M 61.69M 57.72M 108M 7.18B 110M 741M 287M 3.55B 286M 280M 12.32B	EV / Sales 2026 *	55.7x	EV / Sales 2027 *	51.5x
Free-Float	67.54%	Yield 2026 *	-	Yield 2027 *	-

Jun. 18	AB Science Secures US Patent for Prostate Cancer Therapy	MT
Jun. 18	AB Science Secures New U.S. Patent for Masitinib
Jun. 17	AB Science Patent For Masitinib In The Treatment Of Metastatic Castrate Resistant Prostate Cancer Formally Granted In The United States With Protection Until 2042	CI
Jun. 10	AB Science presents new data on Masitinib
May. 17	AB Science S.A. announced that it has received $2.989368 million in funding	CI
May. 13	AB Science S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
May. 03	AB Science S.A. announced that it expects to receive $2.989368 million in funding	CI
Apr. 29	Airbus, Pernod Ricard, Sopra Steria, TotalEnergies, TP... stocks to watch today in Paris
Apr. 29	AB Science announces successful capital increase
Apr. 28	Air Liquide, Nexans, AB Science... stocks to watch today in Paris
Apr. 28	AB Science Reaches Maturity Extension Deal with Lenders	MT
Apr. 27	Vinci, Lumibird, SergeFerrari... stocks to watch tomorrow in Paris
Apr. 27	AB Science announces major agreement with creditors

Jun. 17	AB Science patent for masitinib in the treatment of metastatic castrate resistant prostate cancer formally granted in the United States with a protection until 2042	GL
Jun. 09	AB Science is invited to present at the 2026 ENCALS annual meeting the survival data from masitinib clinical program in ALS	GL
Jun. 02	AB Science : Stonegate Capital Partners updates its coverage of AB Science’s stock with a target price of EUR 4.25 per share	GL
May. 26	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of EUR4.00 per share	AQ
May. 25	AB Science announces that its stock continues to be covered by Maxim Group, with a target price of €4.00 per share	GL

AB Science Stock

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

Quarterly revenue - Rate of surprise

Jun. 26	Agenda des dividendes et des AG France : embouteillage de fin de semestre
Jun. 18	Bourse : L'Oréal met le cap sur l'Inde, gros contrat pour Alstom, rumeur sur Edenred
Jun. 18	Star Warsh
Jun. 18	AB Science obtient un nouveau brevet américain pour son masitinib
Jun. 17	Le brevet d’AB Science concernant le masitinib dans le traitement du cancer de la prostate métastatique hormono-résistant a été officiellement délivré aux Etats-Unis avec une durée de protection jusqu’en 2042

1 day	+1.86%
1 week	-2.35%
Current month	-9.34%
1 month	-9.99%
3 months	-24.39%
6 months	-32.46%
Current year	-43.10%

1 week	0.83	0.88
1 month	0.83	0.96
Current year	0.83	1.61
1 year	0.83	1.73
3 years	0.77	4.46
5 years	0.77	16.68
10 years	0.77	21.75

Manager	Title	Age	Since
Alain Moussy CEO	Chief Executive Officer	-	2001-07-10
Laurent Guy DFI	Director of Finance/CFO	-	2009-11-19
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	2018-03-31

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	2001-07-10
Patrick Moussy BRD	Director/Board Member	-	2011-09-19
Cécile de Guillebon BRD	Director/Board Member	64	2021-06-26

Date	Insider	Type	Main position	Quantity	% Market Cap.
May. 19	Alain Moussy	Sell	Chief Executive Officer	-573	0.0009%
21-02-08	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
21-02-01	Jean-Pierre Kinet	Sell	Founder	12,904	0.0280%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	+1.86%	-2.35%	-37.75%	-78.97%	76.29M
MERCK & CO., INC.	+2.56%	+12.99%	+62.65%	+14.43%	318B
MERCK KGAA	-0.92%	+9.59%	+29.29%	-3.22%	72.22B
HALOZYME THERAPEUTICS, INC.	+3.20%	+9.35%	+43.57%	+119.05%	8.89B
KYOWA KIRIN CO., LTD.	-0.43%	+0.43%	+4.28%	-5.30%	8.25B
SK BIOPHARMACEUTICALS CO., LTD.	-6.43%	-4.71%	-9.20%	+1.59%	4.23B
BETTA PHARMACEUTICALS CO., LTD.	-6.42%	+5.27%	+0.35%	+21.57%	3.58B
YUHAN CORPORATION	-6.87%	-12.75%	-35.91%	+19.59%	3.23B
SUPERNUS PHARMACEUTICALS, INC.	+4.67%	+5.54%	+50.32%	+55.31%	2.72B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-4.41%	+5.98%	+9.54%	-26.83%	2.03B
Average	-1.32%	+2.26%	+11.72%	+11.72%	42.3B
Weighted average by Cap.	+1.66%	+11.47%	+53.07%	+13.25%

	2026 *	2027 *
Net sales	1.2M 1.37M 1.11M 1.04M 1.94M 129M 1.98M 13.3M 5.14M 63.67M 5.13M 5.02M 221M	1.3M 1.48M 1.2M 1.12M 2.1M 140M 2.15M 14.4M 5.57M 68.97M 5.56M 5.44M 239M
Net income	-	-
Net Debt	-	-